Pharmaceuticals

Concord Pharmaceutical's Innovation Transformation Proves Successful, Returns to Growth Track

Contera Pharmaceutical Secures Exclusive Commercialization Rights for Two Intravenous Iron Products in China

Concord Pharmaceutical MG-K10 Seasonal Allergic Rhinitis Application for Market Approval Accepted by NMPA

CLSA Raises Target Price for Konjo Pharma to HKD16.5 and Maintains 'Outperform' Rating

Conchego Pharmaceutical's Dexduosu Tablet Approved by NMPA

CMS released FY2025 9 Months Earnings on March 16 (BJT), with actual revenue of HKD 6.634 B and EPS of HKD 0.545

CMS released FY2025 Q3 earnings on March 16 (BJT), actual revenue HKD 2.301 B, actual EPS HKD 0.1236

Konopharma Announces 2025 Performance and Future Strategies

CMS released FY2025 Annual Earnings on March 16 During-Market (BJT), Actual Revenue HKD 8.975 B (Forecast HKD 9.181 B), Actual EPS HKD 0.6725 (Forecast HKD 0.7769)

CMS released FY2025 Q4 earnings on March 16 During-Market (BJT), actual revenue HKD 2.341 B, actual EPS HKD 0.1258

CMS to release FY2025 earnings report on March 16 During-Market (BJT), forecast revenue HKD 9.44 B, EPS HKD 0.7987

ConchChem Gets Approval for CMS-D008 Clinical Trials for Obesity

Konopharma's Delim Medical's Ruxolitinib Phosphate Cream Receives NDA Acceptance for AD Indication

HSBC Research Forecasts 2026 Sales of ConchChem's Ruxolitinib Cream to Reach 500 Million CNY

Concord Pharmaceutical's CMS-D017 Capsule Approved for Clinical Trials

CICC Upgrades Kangle Pharma Target Price and Sees Potential in Its New Drug

Konopharma Obtains Clinical Trial Approval for CMS-D017 Capsules

Concord Pharmaceutical's CMS-D017 Receives Clinical Trial Approval

Concord Pharmaceutical's Dermage Obtains New Drug Approval for Ruxolitinib Phosphate Cream

DM Medpharma's Povorcitinib Approved for Breakthrough Therapy in China

I.CENTURY HLDG

RIVERINE CHINA

KOS TALENT GP

CHINA CBS INTL

NATURE ENERGY T

DIGIT HOLLYWOOD

REDCO HEALTHY

ZXZN QI-HOUSE

ASIA PIONEER

HUISHENG INTL

159316

159849

516930

512290

159506

00867

520880

China Medical System Holdings (SEHK:867) has received regulatory approval for Desidustat Tablets, enhancing its nephrology segment. The share price is HK$13.27, reflecting a 2.47% increase over one day but a 14.05% decline over 30 days. Despite a strong 82.01% return over the past year, the stock trades at a P/E of 19x, higher than the industry average of 11.5x. Analysts project earnings growth of 21.42% annually. The SWS DCF model estimates a fair value of HK$34.88, indicating a 62% discount at the current price, suggesting potential undervaluation despite risks.

Simplywall

E Fund Hang Seng SCHK Innovative Drug ETF

China Merchants CSI Biotechnology Theme ETF

Minsheng Royal CSI Biotechnology Theme ETF

Guotai CSI Bio-medicine ETF

Fullgoal Hang Seng SCHK Innovative Drug & Healthcare ETF

Hwabao WP Hang Seng SCHK Innovative Drug Select ETF

China Medical System Holdings (SEHK:867) Valuation After Desidustat Approval And Recent Share Price Pullback

513700

China Medical System Holdings (SEHK:867) reported FY 2025 first half revenue of C¥4.0b and basic EPS of C¥0.39, showing growth from C¥3.6b and C¥0.29 in FY 2024. However, net profit margin declined from 21.7% to 18.1%, raising concerns about earnings quality despite an 11.4% revenue growth. The stock trades at a trailing P/E of 19.5x, below the peer average, with a current price of HK$13.72 against an analyst target of HK$17.66 and a DCF fair value of HK$34.31. Investors are advised to consider long-term trends and mixed signals in revenue growth and margins.

Penghua CSI HK Connect Health Care Composite ETF

China Medical System Holdings SEHK 867 Margin Decline Tests Bullish Growth Narrative

CMS announced its performance for the fiscal year 2025, with a revenue of RMB 8.212 billion, an increase of 9.9% year-on-year; gross profit of RMB 5.872 billion, up 8.3%. It recorded a net profit of RMB 1.489 billion, a decline of 8.1%, with earnings per share of 61.54 cents. The final dividend declared is 13.66 cents, compared to 11.74 cents in the same period last year

AASTOCKS

"Performance" CMS's annual net profit is RMB 1.489 billion, down 8%, with a final dividend of 13.66 cents

DRMAW

DRMA

159892

520690

510660

159992

512010

513120

China Medical System Holdings (HK:0867) reported a 9.9% increase in turnover to RMB8.21 billion and an 8.3% rise in gross profit for 2025, despite a 10.5% drop in headline profit due to a one-off tax payment. The board proposed a higher dividend per share, supported by a strong cash position. Innovative products contributed nearly 60% of revenue, with a 44.1% sales increase in that segment. The company is expanding internationally, with plans for a separate Hong Kong listing for its Dermavon unit and a secondary listing in Singapore. Analysts rate the stock as a Buy with a target price of HK$17.00.

Tip Ranks

DERMATA THERAPEUTICS INC C/WTS (TO PUR COM)

Dermata Therapeutics

CS精准医

Geratherm Medical AG

Bosera Hang Seng Health Care ETF(QDII)

Direxion S&P Biotech Bear 3X

Direxion S&P Biotech Bull 3X

ChinaAMC Hang Seng Biotechnology Technology ETF(QDII)

VanEck Biotech ETF

SPDR S&P Biotech

Proshares Ultra Nasdaq Biotech

iShares US Pharma

Invesco Biotechnology & Genome ETF

Health Care Select Sector SPDR

Bosera Hang Seng SCHK Innovative Drug Select ETF

VG Health

ChinaAMC CSI Biotechnology Theme ETF

ChinaAMC SSE STAR Biology and Medicine ETF

ChinaAMC SSE Health Care ETF Initiating Fund

China Universal 800 Health Care ETF

iShares Global Healthcare

E Fund CSI Biotechnology Theme ETF

Yinhua CSI Innovative Drugs Industry ETF

Guotai SSE STAR Brand Name Drug ETF

E Fund CSI 300 Health Care ETF

GF CSI HK Innovative Drugs Industry ETF(QDII)

iShares Biotechnology ETF

ALPS Medical Breakthrough

First Trust NYSE Arca Biotech Index Fd

China Medical System Lifts Revenue and Dividend as Innovation and Overseas Push Gather Pace

Insilico Medicine has partnered with China Medical System (CMS) to launch AI drug discovery collaborations targeting central nervous system (CNS) and autoimmune diseases. The collaboration will utilize Insilico's Pharma.AI platform for small-molecule design and candidate screening, combined with CMS's expertise in clinical development. Insilico will receive R&D funding for each program, aiming to streamline the drug development process and enhance clinical success rates. Both companies plan to deepen their collaboration in clinical strategy and global partnerships to improve patient access to innovative treatments.

Pharmaceutical Technology

Insilico and CMS launch drug discovery collaborations for CNS diseases

CMS(00867.HK)

China Medical System Holdings (SEHK:867) Valuation After Desidustat Approval And Recent Share Price Pullback

China Medical System Holdings SEHK 867 Margin Decline Tests Bullish Growth Narrative

"Performance" CMS's annual net profit is RMB 1.489 billion, down 8%, with a final dividend of 13.66 cents

China Medical System Lifts Revenue and Dividend as Innovation and Overseas Push Gather Pace

Insilico and CMS launch drug discovery collaborations for CNS diseases